# Inflammatory Signal Inhibitors for COVID-19 (MATIS)

> **NCT04581954** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 185 (actual)

## Conditions studied

- Coronavirus
- Covid19
- Pneumonia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Fostamatinib
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04581954
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-02
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-09-02
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04581954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04581954, "Inflammatory Signal Inhibitors for COVID-19 (MATIS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04581954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*